Inhibitory characteristics and oxidant resistance of site specific variants of recombinant human antileukoproteinase (ALP).
Tandem gene plasmids were constructed and used to express inactive proteins equivalent to human antileukoproteinase (ALP) and the variants [Leu73]-ALP and [Leu73, 82, 94, 96]-ALP in E. coli K12. After extraction, refolding, and purification, highly pure and active inhibitors were obtained in good yields. Inhibitory constants for human leukocyte elastase and cathepsin G were found to be similar. The variants in which methionines were exchanged for leucines were shown to be more resistant to inactivation by oxidizing agents than native ALP. As oxidizing conditions exist at sites of inflammation, these ALP variants are promising candidates for therapies involving suppression of elastase-mediated injury.
Heinzel-Wieland
R
R
Grünenthal Research Center, Aachen, FRG.
Steffens
G J
GJ
Flohé
L
L
D004926:Escherichia coli / Q000235:genetics; D014644:Genetic Variation; D006801:Humans; D007700:Kinetics; D016297:Mutagenesis, Site-Directed; D010084:Oxidation-Reduction; D010957:Plasmids; D053491:Proteinase Inhibitory Proteins, Secretory; D011506:Proteins / Q000235:genetics* / Q000378:metabolism; D011994:Recombinant Proteins / Q000235:genetics / Q000378:metabolism; D015842:Serine Proteinase Inhibitors / Q000235:genetics* / Q000378:metabolism
D053491:Proteinase Inhibitory Proteins, Secretory; D011506:Proteins; D011994:Recombinant Proteins; D015842:Serine Proteinase Inhibitors